Skip to main content
Qurient Co., Ltd. logo

Qurient Co., Ltd. — Investor Relations & Filings

Ticker · 115180 ISIN · KR7115180002 KO Professional, scientific and technical activities
Open in API
Filings indexed 437 across all filing types
Latest filing 2023-05-12 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 115180

About Qurient Co., Ltd.

http://www.qurient.com/

Qurient Co., Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for unmet medical needs. The company operates on a proprietary 'Network R&D' model, a virtual approach that manages drug development programs from early discovery through clinical phases. Its pipeline includes Adrixetinib for chronic graft-versus-host disease (cGvHD), Telacebec for the treatment of tuberculosis, and a next-generation dual-payload Antibody-Drug Conjugate (ADC) platform for oncology. Qurient advances its portfolio through global clinical trials and strategic collaborations to address critical diseases.

Recent filings

Filing Released Lang Actions
분기보고서 (2023.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company 'Qurient' covering the period from January 1, 2023, to March 31, 2023. It contains detailed financial information, business operations, and management discussions, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-12 Korean
소속부변경
Regulatory Filings Classification · 100% confidence The document is a short regulatory announcement regarding a change in the company's market classification (from 'Mid-sized Enterprise' to 'Venture Enterprise') on the stock exchange. It does not fit into specific categories like financial reports, dividends, or M&A, and is too brief to be a comprehensive report. Therefore, it falls under the general regulatory filing category.
2023-04-28 Korean
투자판단관련주요경영사항(항암치료제 Q901 단독요법 및 펨브롤리주맙(키트루다)과의 병용요법에 대한 식품의약품안전처(MFDS) 임상 제1/2상 임상시험계획(IND) 신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (KIND) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It specifically details the submission of an Investigational New Drug (IND) application to the Korean Ministry of Food and Drug Safety (MFDS) for a clinical trial. Since this is a formal regulatory announcement of a material business event (clinical trial application) that does not fit into specific categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2023-04-03 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service (FSS) in South Korea. This type of filing is a mandatory disclosure when a director or major shareholder acquires or disposes of company shares. According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2023-03-31 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results from a company's Annual General Meeting (AGM). It details the approval of financial statements, election of directors and auditors, and amendments to business purposes. This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA), as it provides the outcome of shareholder votes held during the meeting.
2023-03-27 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to directors and employees, including the number of shares, exercise price, and valuation methodology. Since this is a specific regulatory disclosure regarding capital structure and equity-based compensation that does not fit into the other categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for new capital issuance), it is classified as a general Regulatory Filing (RNS).
2023-03-27 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.